NCT02489357View on ClinicalTrials.gov

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Stage IV Prostate Cancer
Interventions
PROCEDURE

Cryosurgery

Undergo whole gland cryoablation

DRUG

Degarelix

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02489357 - Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter